product summary
Loading...
company name :
Tocris Bioscience
product type :
chemical
product name :
Purvalanol A
catalog :
1580/10
quantity :
10 mg (also 50 mg)
price :
255 USD
more info or order :
citations: 8
Reference |
---|
Pennati M, Campbell A, Curto M, Binda M, Cheng Y, Wang L, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005;4:1328-37 pubmed
|
product information
brand :
Tocris, a Bio-Techne brand
catalog number base :
1580
SKU :
1580/10
product name :
Purvalanol A
description :
Cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5
target :
Cyclin-dependent Kinase Inhibitors
unit size :
10 mg (also 50 mg)
category :
Small Molecules
purity :
98%
storage :
Store at +4°C
observed molecular weight :
388.9
url print :
?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules
details of functionality :
Purvalanol A is a cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 4, 4 - 70, 75 - 240 and 100 nM for cdk1, cdk2, cdk5 and cdk 7, respectively). Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death.
product keywords :
Cyclin-dependent protein kinases inhibitors inhibits Cdk PurvalanolA NG60 NG 60 Cyclin-dependent Kinase Non-selective CDKs 1580,
extended description :
Cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5
chemical name text :
(2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol
formula :
C19H25ClN6O
formula text :
C19H25ClN6O
cas num :
212844-53-6
USD :
252
USD 2025 :
255 USD
product details :
Cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5
alt names :
NG 60
more info or order :
company information

Tocris Bioscience
The Watkins Building
Atlantic Road
Avonmouth, Bristol
BS11 9QD
Atlantic Road
Avonmouth, Bristol
BS11 9QD
info@bio-techne.com
https://www.tocris.com800-343-7475
headquarters: UK
related products
browse more products
questions and comments